Video

Analyzing GEMINI 1 clinical trial results of presbyopia eye drop

Author(s):

Sheryl Stevenson,Alex Delaney-Gesing
Conferences|ASCRS

George O. Waring IV, MD, FACS, discusses the latest results from the GEMINI 1 clinical trial of AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia.

George O. Waring IV, MD, FACS, of the Waring Vision Institute (Mount Pleasant, SC), discusses the latest results from the GEMINI 1 clinical trial (by Allergan, an Abbvie company) of AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia.

See more ASCRS coverage

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Related Content
(Image credit: AdobeStock/InkInvent) FDA clears path for US IDE study of Myra Vision’s titratable glaucoma therapy
August 14th 2025

FDA clears path for US IDE study of Myra Vision’s titratable glaucoma therapy

3 Things You Should Know About the GA Pipeline
August 14th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

(Image credit: AdobeStock/ipopba) Robotic precision: Elevating the state of laser cataract surgery
August 14th 2025

Robotic precision: Elevating the state of laser cataract surgery

Patient-Centered Treatment Strategies in the Management of nAMD and DME
August 14th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

(Image credit: AdobeStock/NicoElNino) Dialing in precision: Astigmatism management with arcuate incisions
August 14th 2025

Dialing in precision: Astigmatism management with arcuate incisions

Q&A: Sruthi Arepalli, MD, discusses outcomes in patients with noninfectious uveitis requiring secondary lens implantation
August 14th 2025

Q&A: Sruthi Arepalli, MD, discusses outcomes in patients with noninfectious uveitis requiring secondary lens implantation

© 2025 MJH Life Sciences

All rights reserved.